The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1640
December 27, 2021
View Complete Issue         Table of Contents 2019 
Xywav - A Mixed-Salt Oxybate Oral Solution for Idiopathic Hypersomnia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Xywav - A Mixed-Salt Oxybate Oral Solution for Idiopathic Hypersomnia
December 27, 2021 (Issue: 1640)
Xywav (Jazz), an oral solution that contains calcium, magnesium, potassium, and sodium oxybates, has been approved by the FDA for treatment of idiopathic hypersomnia in adults. It is the first drug to be approved in the US for this indication....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Xywav - A Mixed-Salt Oxybate Oral Solution for Idiopathic Hypersomnia
Article code: 1640d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.